Le Lézard
Classified in: Science and technology, Business
Subject: PER

Bitdefender Appoints John Stynes as Chief Financial Officer


BUCHAREST, Romania and SANTA CLARA, California, March 20, 2019 /PRNewswire/ -- Bitdefender, a leading global cybersecurity company protecting over 500 million systems across 150 countries, has appointed John Stynes as its Chief Financial Officer.

Bitdefender logo (PRNewsfoto/Bitdefender)

Stynes brings significant expertise in leading performant public companies of all sizes. From his base in London, Stynes joins the management team leading Bitdefender efforts to transform its business procedures.

In his most recent role as Verifone CFO for Europe and Russia, Stynes was key in driving finance transformation, business/strategic insights and European investor relations. His work in Europe created a strong platform as the company transitioned from public to private in August 2018.

Before Verifone, Stynes was deputy CFO at TT Electronics, a FTSE-listed manufacturer, where he served as a core member of the team managing board, banks and investors expectations as the company undertook a significant development. He spent the majority of his career at Cisco, setting up Cisco Capital and Treasury, implementing SOX as their EMEA Corporate Controller and serving as CFO for their Northern European and UKI operations organizations.

"I am delighted to join Bitdefender in this accelerated growth and transformation stage. I see tremendous potential for the cybersecurity industry in the coming years and Bitdefender has a strong position within it. About 38% of the world's cybersecurity solutions and their users already use award-winning Bitdefender technologies," said Stynes.

Former CFO Niculae Dinca will remain part of the finance management team and support Stynes during the transition. He has successfully led the company's finance operations through the past 10 years of tremendous growth and multiple funding rounds.

Stynes joins Bitdefender following a significant number of additions to its management ranks in the past three years. The company invested in its enterprise and corporate marketing teams and significantly expanded its European and US offices.

About Bitdefender

Bitdefender is a global cybersecurity and antivirus software leader protecting over 500 million systems in more than 150 countries. Since 2001, Bitdefender innovation has consistently delivered award-winning security products and threat intelligence for people, homes, businesses and their devices, networks and cloud services. Today, Bitdefender is also the provider-of-choice, used in over 38% of the world's security solutions. Recognized by industry, respected by vendors and evangelized by our customers, Bitdefender is the cybersecurity company you can trust and rely on. www.bitdefender.com.

 

SOURCE Bitdefender


These press releases may also interest you

at 21:30
Rubrik, Inc. today announced the pricing of its upsized initial public offering of 23,500,000 shares of its Class A common stock at a public offering price of $32.00 per share. In addition, Rubrik has granted the underwriters a 30-day option to...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:26
OKX, a leading Web3 technology company, has issued updates for April 24, 2024. OKX DeFi Launches 'zkSwap Bonus Event' Offering Users...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
The Board of Directors of TransAlta Corporation declared a quarterly dividend of $0.06 per common share payable on July 1, 2024 to shareholders of record at the close of business on June 1, 2024. The Board of Directors also declared the following...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...



News published on and distributed by: